Daré Bioscience, Inc.
DARE · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.05 | 0.13 | 0.06 | -0.07 |
| FCF Yield | -2.30% | -24.83% | -22.23% | 17.59% |
| EV / EBITDA | -1.81 | -5.70 | -5.27 | -2.25 |
| Quality | ||||
| ROIC | -30.57% | 100.16% | 1,834.38% | -517.72% |
| Gross Margin | 0.00% | 100.00% | -8,935.20% | 22,445.96% |
| Cash Conversion Ratio | 0.12 | 1.35 | 1.25 | -0.95 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | -86.27% | -90.07% |
| Free Cash Flow Growth | 88.28% | 6.46% | -220.67% | 182.67% |
| Safety | ||||
| Net Debt / EBITDA | 5.49 | 0.59 | 0.46 | 2.67 |
| Interest Coverage | 0.00 | -14.25 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 14,687.94 | -799.66 | 298.71 | -334.42 |